Olanzapinefluoxetine combination for the treatment of bipolar depression

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 17, 2011, Pages 2751-2758

  Citrome, Leslie ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Antidepressant; Bipolar depression; Lamotrigine; Olanzapinefluoxetine combination; Quetiapine

Indexed keywords

FLUOXETINE PLUS OLANZAPINE; LAMOTRIGINE; OLANZAPINE; PLACEBO; QUETIAPINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; FLUOXETINE; NEUROLEPTIC AGENT;

ARTICLE; ASTHENIA; ATTENTION DISTURBANCE; BIPOLAR DEPRESSION; BLURRED VISION; CHOLESTEROL BLOOD LEVEL; DIARRHEA; DRUG APPROVAL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EVENING DOSAGE; FATIGUE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERSOMNIA; INCREASED APPETITE; INSOMNIA; MAINTENANCE DRUG DOSE; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MUSCLE TWITCH; NAUSEA; NERVOUSNESS; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEDATION; SIDE EFFECT; SOMNOLENCE; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; XEROSTOMIA; ANIMAL; BIPOLAR DISORDER; DRUG COMBINATION; REVIEW;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; DIBENZOTHIAZEPINES; DRUG COMBINATIONS; FLUOXETINE; HUMANS;

EID: 81255150098     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.632368     Document Type: Article

References (22)

1. Hirschfeld RM, Calabrese JR, Weissman MM, et al. Screening for bipolar disorder in the community. J Clin Psychiatry 2003;64:53-9
2. Ghaemi SN, Boiman EE, Goodwin FK. Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. J Clin Psychiatry 2000;61:804-8
3. Eli Lilly and Co. Symbyax (olanzapine and fluoxetine). Revised August 2011. Available from: http://pi.lilly.com/us/ symbyax-pi.pdf [Last accessed 12 September 2011]
4. AstraZeneca. Seroquel (quetiapine). Revised July 2011. Available from: http://www1.astrazeneca-us.com/pi/ Seroquel.pdf [Last accessed 12 September 2011]
5. AstraZeneca. Seroquel XR (quetiapine extended release). Revised July 2011. Available from: http://www1.astrazenecaus. com/pi/seroquelxr.pdf [Last accessed 12 September 2011]
6. Eli Lilly and Co. Zyprexa (olanzapine). Revised June 2011. Available from: http://pi.lilly.com/us/zyprexa-pi.pdf [Last accessed 12 September 2011]
7. Citrome L. Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med 2010;122:39-48
8. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-88
9. Brown EB, McElroy SL, Keck PE Jr, et al. A 7-week, randomized, double-blind trial of olanzapine/ fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006;67:1025-33
10. Brown E, Dunner DL, McElroy SL, et al. Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression. Int J Neuropsychopharmacol 2009;12:773-82
11. Eli Lilly and Co. Summary ID#3077. Clinical Study Summary: Study F1D-MC-HGGY (acute). Available from: http://www.clinicalstudyresults.org/ documents/company-study-169-0.pdf [Last accessed 12 September 2011]
12. Eli Lilly and Co. Summary ID# 7980. Clinical Study Summary: Study H6P-US-HDAQ. Available from: http:// www.clinicalstudyresults.org/documents/ company-study-1540-0.pdf [Last accessed 12 September 2011]
13. Citrome L, Holt RI, Walker DJ, Hoffmann VP. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clin Drug Investig 2011;31:455-82
14. Kantrowitz JT, Citrome L. Olanzapine: review of safety 2008. Expert Opin Drug Saf 2008;7:761-9
15. Citrome L. Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Curr Drug Saf 2009;4:229-37
16. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar epression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009;194:4-9
17. Ketter TA, Citrome L, Wang PW, et al. Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions? Acta Psychiatr Scand 2011;123:175-89
18. GlaxoSmithKline. Lamictal (lamotrigine). Revised July 2011. Available from: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2011/ 020241s047,020764s040,022251s010lbl. pdf [Last accessed 12 September 2011]
19. Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand 2008;117:412-19
20. Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008;28:13-20
21. Sachs G, Lombardo I, Yang R, Kremer C. Learnings from the ziprasidone bipolar I depression clinical trials program. Poster presentation II-13. 49th Annual NCDEU Meeting; 2009 June 29-July 2; Hollywood, Florida
22. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract 2011;65:189-210